PT  - JOURNAL ARTICLE
AU  - HIDEO MATSUMOTO
AU  - HISAKO KUBOTA
AU  - MASAHARU HIGASHIDA
AU  - EISAKU YODEN
AU  - JUNICHI HIRATSUKA
AU  - KEN HARUMA
AU  - MASAFUMI NAKAMURA
AU  - TOSHIHIRO HIRAI
TI  - Docetaxel/ TS-1 with Radiation for Unresectable Squamous Cell Carcinoma of the Esophagus - A Phase II Trial
DP  - 2014 Jul 01
TA  - Anticancer Research
PG  - 3759--3763
VI  - 34
IP  - 7
4099  - http://ar.iiarjournals.org/content/34/7/3759.short
4100  - http://ar.iiarjournals.org/content/34/7/3759.full
SO  - Anticancer Res2014 Jul 01; 34
AB  - Background: We tried a new regimen of docetaxel / TS-1 (tegafur-gimestat-otastat potassium) combined with radiation for squamous cell carcinoma of the esophagus in a phase II trial. Patients and Methods: The patients, whose tumor invaded other organs without other organ metastasis, were given TS-1 (60 mg/m2/day) from days 1 to 14, and docetaxel (20-30 mg/m2) on days 1 and 8. They received radiation in 2.0 Gy from days 1 to 21. Patients were given a seven-day rest after the first course, and then were treated with the same regimen from days 28 to 49. Results: Seventeen cases were enrolled in the study. The response rate was 76.4% (13/17). The overall 5-year survival rate was 29.6% (5/17) and median survival time was 15.2 months. Adverse events more than grade 3 occurred in 10 cases. Conclusion: This combination therapy may be one of the most effective treatments because of its lower rate of non-hematological adverse events and higher response rate. Three cases also underwent salvage surgery when the tumor recurred, and in one case, chemoradiation to a metastatic nodule on the thoracic wall was added.